Herndon Leon W, Wand Martin, Asrani Sanjay
Duke University Eye Center, Durham, North Carolina 27710, USA.
Am J Ophthalmol. 2003 May;135(5):713-5. doi: 10.1016/s0002-9394(02)02146-3.
To report increased eyelid pigmentation as an adverse side effect associated with topical ocular hypotensive lipids in African Americans.
Interventional case series.
Two African-American patients with open-angle glaucoma are described in whom increased eyelid pigmentation developed 1 month to 5 months after beginning treatment with either latanoprost or bimatoprost.
Latanoprost was discontinued in an African-American patient, and pigmentation gradually diminished by 3 months after cessation of latanoprost. Increased eyelid pigmentation and increased eyelash length were noted in another African-American patient after just 4 weeks on bimatoprost.
An increase in eyelid pigmentation and eyelash growth is a possible complication of topical ocular hypotensive lipid therapy, even in African-American patients. The changes seems to present earlier after bimatoprost treatment then after latanoprost treatment. Cessation of these medications may lead to loss of induced pigmentation.
报告非裔美国人中与局部降眼压脂质相关的眼睑色素沉着增加这一不良副作用。
干预性病例系列。
描述了两名开角型青光眼的非裔美国患者,他们在开始使用拉坦前列素或比马前列素治疗1个月至5个月后出现眼睑色素沉着增加。
一名非裔美国患者停用了拉坦前列素,停药后3个月色素沉着逐渐减轻。另一名非裔美国患者在使用比马前列素仅4周后就出现了眼睑色素沉着增加和睫毛变长。
眼睑色素沉着增加和睫毛生长是局部降眼压脂质治疗的一种可能并发症,即使在非裔美国患者中也是如此。比马前列素治疗后这些变化似乎比拉坦前列素治疗后出现得更早。停用这些药物可能导致诱导性色素沉着消失。